QIAGEN launches monkeypox test for NeuMoDx platform to fight global outbreak by boosting research and surveillance
21 November 2022 - 10:05PM
Business Wire
- NeuMoDx MPXV Test Strip enables researchers to quickly
identify both clade I & II of the monkeypox virus
- Dual-target design to reduce false negatives
- Multiplex test strengthens QIAGEN’s portfolio designed to
boost the fight against global monkeypox outbreak
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced the launch of the monkeypox (MPXV) test for its NeuMoDx
automated PCR platform to strengthen surveillance and research into
the current outbreak in non-endemic regions that has infected tens
of thousands of people all over the world since first being
identified in May 2022.
The NeuMoDx MPXV Test Strip – currently for research use only
(RUO) – is a multiplex test that identifies both clades (variants)
of monkeypox. It is designed as a dual-target assay to reduce false
negative results, incorrectly indicating the absence of the virus.
It differentiates between the clade I and clade II variants,
delivering first results in around 70 minutes on QIAGEN’s easy to
use, fast and flexible NeuMoDx 96 and NeuMoDx 288 Molecular
Systems.
“NeuMoDx MPXV enables researchers the fast and reliable
qualitative detection and differentiation of both monkeypox clades,
a huge help for those trying to understand and contain this virus,”
said Jean-Pascal Viola, Senior Vice President, Head of the
Molecular Diagnostics Business Area at QIAGEN.
The NeuMoDx assay extracts DNA from lesion fluid swabs to
isolate the target nucleic acids and then conducts a real-time
polymerase chain reaction. NeuMoDx has a simple 3-step workflow.
Test strips and core reagents and consumables are ready-to-use, can
remain on board for a minimum of 7 days and can be loaded whilst
the system is operating. The NeuMoDx system is always ready to run
and offers true random access testing capabilities, has up to 8
hours walkaway time and produces minimal waste. The system can run
up to 30 different assays and offers the versatility to run IVD
certified assays, self-developed tests (SDTs) and RUO assays.
QIAGEN has been working with healthcare authorities around the
world since the global monkeypox outbreak began this spring to
contribute its broad testing portfolio and expertise as a trusted
partner in an urgent global health response. Its new assay joins a
portfolio that addresses all testing needs. QIAGEN this summer
launched the QIAstat-Dx Viral Vesicular Panel RUO, the world’s
first syndromic test, for research use only, to differentiate
between monkeypox and five other pathogens that cause similar
symptoms.
QIAGEN’s sample-technology kits, testing components and
instruments are also being used by public health agencies to
develop their own tests. The NeuMoDx clinical PCR system can run
these so-called self-developed tests (SDTs), while enabling
molecular diagnostic laboratories to process ever-larger volumes
and deliver ever-faster insights into monkeypox and other
infectious diseases.
Some 78,000 people in more than 110 countries have been infected
with the virus since the latest outbreak began this spring,
according to the World Health Organization (WHO). The sustained
global transmission is different from other outbreaks recorded
since the 1970s. Should authorities open new pathways in light of
this public-health emergency, QIAGEN stands ready to widen the
availability of its applications beyond researchers to healthcare
professionals treating patients in clinical settings.
To learn more about the NeuMoDx MPXV Test Strip, please visit:
https://www.qiagen.com/applications/automated-pcr/assay-menu/monkeypox
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare),
Applied Testing (primarily forensics), Pharma (pharma and biotech
companies) and Academia (life sciences research). As of September
30, 2022, QIAGEN employed more than 6,200 people in over 35
locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to,
the U.S. Securities and Exchange Commission (SEC).
Source: QIAGEN N.V.
Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221121005701/en/
Contacts QIAGEN: Investor Relations John Gilardi
+49 2103 29 11711 Phoebe Loh +49 2103 29 11457 e-mail:
ir@QIAGEN.com
Public Relations Thomas Theuringer +49 2103 29 11826
Daniela Eltrop +49 2103 29 11676 e-mail: pr@QIAGEN.com
Qiagen NV (TG:QIA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Qiagen NV (TG:QIA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024